59 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
10
Discovery of Selective Small Molecule Inhibitors of Monoacylglycerol Acyltransferase 3.
Pfizer
24
Discovery and optimization of adamantane carboxylic acid derivatives as potent diacylglycerol acyltransferase 1 inhibitors for the potential treatment of obesity and diabetes.
Korea Research Institute of Chemical Technology
25
Discovery of a Novel Series of N-Phenylindoline-5-sulfonamide Derivatives as Potent, Selective, and Orally Bioavailable Acyl CoA:Monoacylglycerol Acyltransferase-2 Inhibitors.
Takeda Pharmaceutical
46
Development of novel benzomorpholine class of diacylglycerol acyltransferase I inhibitors.
Merck Research Laboratories
22
Discovery of novel quinoline carboxylic acid series as DGAT1 inhibitors.
Merck Research Laboratories
45
Discovery of 6-phenylpyrimido[4,5-b][1,4]oxazines as potent and selective acyl CoA:diacylglycerol acyltransferase 1 (DGAT1) inhibitors with in vivo efficacy in rodents.
Amgen
50
Defining the key pharmacophore elements of PF-04620110: discovery of a potent, orally-active, neutral DGAT-1 inhibitor.
Pfizer
18
Synthesis and biological evaluation of aminobenzimidazole derivatives with a phenylcyclohexyl acetic acid group as anti-obesity and anti-diabetic agents.
Korea Research Institute of Chemical Technology
35
Lead optimization of a pyridine-carboxamide series as DGAT-1 inhibitors.
Merck Research Laboratories
40
Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687).
AstraZeneca
11
Identification and preliminary characterization of a potent, safe, and orally efficacious inhibitor of acyl-CoA:diacylglycerol acyltransferase 1.
Abbott Laboratories
7
Intestinally Targeted Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitors Robustly Suppress Postprandial Triglycerides.
TBA
3
Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1.
TBA
25
Design and synthesis of potent carboxylic acid DGAT1 inhibitors with high cell permeability.
Prosidion
28
Discovery of orally active carboxylic acid derivatives of 2-phenyl-5-trifluoromethyloxazole-4-carboxamide as potent diacylglycerol acyltransferase-1 inhibitors for the potential treatment of obesity and diabetes.
Hoffmann-La Roche
12
Novel Approaches in Biotechnology: Microbial Genetic Modifications and Metabolic Disease Therapies.
Usona Institute
24
A Collection of Novel Antitumor Agents That Regulate Lipid Metabolism in the Tumor Microenvironment.
Shenyang Pharmaceutical University
11
Sesquilignans: Current research and potential prospective.
Shaanxi University of Chinese Medicine
6
Pyrazolopyridine and Triazolopyridine Derivatives as DGAT2 Inhibitors for Treating Multiple Diseases.
Smith, Gambrell & Russell
15
Optimization of a novel series of N-phenylindoline-5-sulfonamide-based acyl CoA:monoacylglycerol acyltransferase-2 inhibitors: Mitigation of CYP3A4 time-dependent inhibition and phototoxic liabilities.
Takeda Pharmaceutical Co., Ltd
6
Novel Triazolopyridine Derivatives as DGAT2 Inhibitors for Treating Multiple Diseases.
Smith, Gambrell & Russell
12
Treatment of Metabolic Disorders Using Novel DGAT2 Inhibitors: Pyrazolopyridine and Triazolopyridine Derivatives.
Usona Institute
6
Novel Imidazopyridine and Imidazopyridazine Derivatives as DGAT2 Inhibitors for Treating Multiple Diseases.
Smith, Gambrell & Russell
14
Design of Next-Generation DGAT2 Inhibitor PF-07202954 with Longer Predicted Half-Life.
Pfizer
6
Benzimidazolone Derivatives as DGAT2 Inhibitors for Treating Diseases.
Smith, Gambrell & Russell
13
Discovery of Ervogastat (PF-06865571): A Potent and Selective Inhibitor of Diacylglycerol Acyltransferase 2 for the Treatment of Non-alcoholic Steatohepatitis.
Pfizer
6
Novel Diacylglycerol Acetyltransferase 2 Inhibitors for Treating Liver Diseases.
Smith, Gambrell & Russell
19
Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH).
TBA
40
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
Terns Pharmaceuticals
16
Discovery and Pharmacology of a Novel Class of Diacylglycerol Acyltransferase 2 Inhibitors.
Merck
28
Discovery of Tetralones as Potent and Selective Inhibitors of Acyl-CoA:Diacylglycerol Acyltransferase 1.
Glaxosmithkline
21
Discovery of dimethyl pent-4-ynoic acid derivatives, as potent and orally bioavailable DGAT1 inhibitors that suppress body weight in diet-induced mouse obesity model.
Wuxi Apptec (Shanghai)
2
Causes and Significance of Increased Compound Potency in Cellular or Physiological Contexts.
Merck
8
Discovery of an Orally Bioavailable Benzimidazole Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitor That Suppresses Body Weight Gain in Diet-Induced Obese Dogs and Postprandial Triglycerides in Humans.
Novartis Institutes For Biomedical Research
22
NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF
Shanghai Hansoh Biomedical
117
BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS
Hoffmann-La Roche
99
INHIBITORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION
Ono Pharmaceutical Co.
30
DIACYLGLYCEROL KINASE (DGK) ALPHA INHIBITORS AND USES THEREOF
Insilico Medicine IP
29
IMIDAZOTRIAZINE AND PYRROLOPYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS
Beigene
118
4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER
Centre National De La Recherche Scientifique
13
Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
Bioaxone Biosciences
366
Sphinogosine-1 -phosphate receptor modulators for treatment of cardiopulmonary disorders
The Scripps Research Institute
472
Inhibitors of Bruton's tyrosine kinase and method of their use
Janssen Pharmaceutica
11
Origins of PDZ Binding Specificity. A Computational and Experimental Study Using NHERF1 and the Parathyroid Hormone Receptor.
The University of Queensland
9
New 1,2-diaryl-4-substituted-benzylidene-5-4H-imidazolone derivatives: Design, synthesis and biological evaluation as potential anti-inflammatory and analgesic agents.
Beni-Suef University
35
Evaluation of multifunctional synthetic tetralone derivatives for treatment of Alzheimer's disease.
Wuhan University of Technology
4
Phosphorylation of Capsaicinoid Derivatives Provides Highly Potent and Selective Inhibitors of the Transcription Factor STAT5b.
University of Leipzig
3
Glucosamine synthetase from Escherichia coli: kinetic mechanism and inhibition by N3-fumaroyl-L-2,3-diaminopropionic derivatives.
Enscp